WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies (NASDAQ: BIAF) raised $4M via a registered direct offering and private placement, selling shares and warrants at $6.122 each. Proceeds will support working capital and lung cancer test sales. WallachBeth Capital acted as placement agent. Closing expected October 9, 2026.
How this was made
The 30-second read
Why it matters
The company is raising approximately $4M gross via common stock (or pre-funded warrants) and issuing warrants exercisable after stockholder approval, which can create near-term selling pressure and longer-dated overhang.
Market read
Traders may reassess dilution risk, timing around stockholder approval, and the likelihood of closing around Oct. 9.
What to watch
The pre-funded warrant structure and very low exercise price for those warrants (in lieu of common shares) can change effective dilution timing and investor behavior around stockholder approval.
Background
WallachBeth Capital is acting as sole placement agent for bioAffinity’s registered direct offering priced at-the-market under Nasdaq rules, with a concurrent warrant private placement.
Ticker impact
bioAffinity Technologies announced a registered direct offering at-the-market priced around $6.122, plus a concurrent warrant private placement raising about $4M gross.
Likely downward pressure as investors price in dilution and warrant overhang, partially offset by the stated use of proceeds.
The release is a primary disclosure of a common-stock sale and warrant structure, with proceeds earmarked for operations, which typically increases share count and can weigh on the stock.
Market effects
Biotech financing conditions and ATM pricing can influence sentiment toward small-cap diagnostic and early-stage healthcare names.
Limited broader market impact; primarily affects US small-cap biotech risk appetite.
Low global relevance; transaction is US-focused and company-specific.
Counterpoint
If the company’s CyPath Lung sales ramp is credible, the financing could be viewed as enabling growth rather than signaling distress, reducing downside versus typical dilution fears.
Key entities
- issuerbioAffinity Technologies, Inc.
NASDAQ-listed biotech developing CyPath Lung, entered into a registered direct offering and concurrent warrant placement.
- placement_agentWallachBeth Capital LLC
Sole placement agent for the offering.
